文献速递流行病学与生物统计真实世界研究与卫生经济

局限性前列腺癌治疗后的功能结局

Functional Outcomes After Localized Prostate Cancer Treatment.
PubMed 文献 · JAMA · 2024-01-01

该观察性队列研究利用美国5个监测、流行病学和最终结果项目登记处数据,纳入2445例局限性前列腺癌患者,比较不同治疗在10年随访时患者报告的功能结局。在预后良好患者中,根治性前列腺切除术与主动监测相比与更差的尿失禁相关,但性功能无显著差异;在预后不良患者中,根治性前列腺切除术与外照射放疗联合雄激素剥夺治疗相比与更差的尿失禁相关,而外照射放疗联合雄激素剥夺治疗与更差的肠道和激素功能相关。

要点

  • 预后良好患者中,根治性前列腺切除术与主动监测相比尿失禁更差,性功能无显著差异。
  • 预后不良患者中,根治性前列腺切除术与外照射放疗联合雄激素剥夺治疗相比尿失禁更差,性功能无显著差异。
  • 预后不良患者中,外照射放疗联合雄激素剥夺治疗与根治性前列腺切除术相比肠道和激素功能更差。

核心结论

  • 在局限性前列腺癌患者中,根治性前列腺切除术在10年随访时与更差的尿失禁相关,但与更差的性功能无关。
  • 在预后不良患者中,外照射放疗联合雄激素剥夺治疗在10年随访时与更差的肠道和激素功能相关。

研究设计与样本

  • 观察性队列研究,使用美国5个监测、流行病学和最终结果项目登记处数据。
  • 纳入2011年至2012年接受治疗的局限性前列腺癌患者,基线时预后良好1877例,预后不良568例。
  • 随访数据通过问卷收集至2022年2月1日,中位随访9.5年。

主要发现

  • 预后良好患者中,根治性前列腺切除术与主动监测相比,调整后平均差值为尿失禁-12.1(95%CI,-16.2至-8.0),性功能-7.2(95%CI,-12.3至-2.0)。
  • 预后不良患者中,根治性前列腺切除术与外照射放疗联合雄激素剥夺治疗相比,调整后平均差值为尿失禁-26.6(95%CI,-35.0至-18.2),性功能-1.4(95%CI,-11.1至8.3)。
  • 预后不良患者中,外照射放疗联合雄激素剥夺治疗与根治性前列腺切除术相比,调整后平均差值为肠道功能-4.9(95%CI,-9.2至-0.7),激素功能-4.9(95%CI,-9.5至-0.3)。

关键数值与推荐

  • 预后良好定义:cT1-cT2bN0M0,前列腺特异性抗原水平<20 ng/mL,分级组1-2。
  • 预后不良定义:cT2cN0M0,前列腺特异性抗原水平20-50 ng/mL,或分级组3-5。
  • 最小临床重要差异:性功能10至12,尿失禁6至9,尿刺激5至7,肠道和激素功能4至6。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Adverse outcomes associated with treatments for localized prostate cancer remain unclear. OBJECTIVE: To compare rates of adverse functional outcomes between specific treatments for localized prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: An observational cohort study using data from 5 US Surveillance, Epidemiology, and End Results Program registries. Participants were treated for localized prostate cancer between 2011 and 2012. At baseline, 1877 had favorable-prognosis prostate cancer (defined as cT1-cT2bN0M0, prostate-specific antigen level <20 ng/mL, and grade group 1-2) and 568 had unfavorable-prognosis prostate cancer (defined as cT2cN0M0, prostate-specific antigen level of 20-50 ng/mL, or grade group 3-5). Follow-up data were collected by questionnaire through February 1, 2022. EXPOSURES: Radical prostatectomy (n = 1043), external beam radiotherapy (n = 359), brachytherapy (n = 96), or active surveillance (n = 379) for favorable-prognosis disease and radical prostatectomy (n = 362) or external beam radiotherapy with androgen deprivation therapy (n = 206) for unfavorable-prognosis disease. MAIN OUTCOMES AND MEASURES: Outcomes were patient-reported sexual, urinary, bowel, and hormone function measured using the 26-item Expanded Prostate Cancer Index Composite (range, 0-100; 100 = best). Associations of specific therapies with each outcome were estimated and compared at 10 years after treatment, adjusting for corresponding baseline scores, and patient and tumor characteristics. Minimum clinically important differences were 10 to 12 for sexual function, 6 to 9 for urinary incontinence, 5 to 7 for urinary irritation, and 4 to 6 for bowel and hormone function. RESULTS: A total of 2445 patients with localized prostate cancer (median age, 64 years; 14% Black, 8% Hispanic) were included and followed up for a median of 9.5 years. Among 1877 patients with favorable prognosis, radical prostatectomy was associated with worse urinary incontinence (adjusted mean difference, -12.1 [95% CI, -16.2 to -8.0]), but not worse sexual function (adjusted mean difference, -7.2 [95% CI, -12.3 to -2.0]), compared with active surveillance. Among 568 patients with unfavorable prognosis, radical prostatectomy was associated with worse urinary incontinence (adjusted mean difference, -26.6 [95% CI, -35.0 to -18.2]), but not worse sexual function (adjusted mean difference, -1.4 [95% CI, -11.1 to 8.3), compared with external beam radiotherapy with androgen deprivation therapy. Among patients with unfavorable prognosis, external beam radiotherapy with androgen deprivation therapy was associated with worse bowel (adjusted mean difference, -4.9 [95% CI, -9.2 to -0.7]) and hormone (adjusted mean difference, -4.9 [95% CI, -9.5 to -0.3]) function compared with radical prostatectomy. CONCLUSIONS AND RELEVANCE: Among patients treated for localized prostate cancer, radical prostatectomy was associated with worse urinary incontinence but not worse sexual function at 10-year follow-up compared with radiotherapy or surveillance among people with more favorable prognosis and compared with radiotherapy for those with unfavorable prognosis. Among men with unfavorable-prognosis disease, external beam radiotherapy with androgen deprivation therapy was associated with worse bowel and hormone function at 10-year follow-up compared with radical prostatectomy.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Al Hussein Al Awamlh B, Wallis CJD, Penson DF, et al. Functional Outcomes After Localized Prostate Cancer Treatment. JAMA. 2024. PMID: 38261043. doi:10.1001/jama.2023.26491

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。